Dr. Ahmed Kilani, Chairman of EIPICO, participated in a meeting chaired by Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority, on Thursday, March 13, 2025.

Representatives from EIPICO and Reliance Life Sciences, India, were also in attendance. During the meeting, ways to enhance cooperation between the two parties to advance pharmaceutical development in Egypt were discussed, ensuring a qualitative leap in the pharmaceutical industry.

The two companies' efforts in supporting the pharmaceutical sector were also commended, particularly with regard to developing pharmaceutical products and supporting innovation.

Dr. Ali El-Ghamrawy emphasized the importance of cooperation between national and international companies to transfer expertise and modern technologies.

He also commended EIPICO's efforts in supporting the development of the pharmaceutical industry in Egypt. He also commended Reliance's significant efforts in pharmaceutical research and its ability to develop numerous biosimilars and market them globally.

The head of the authority emphasized that Egypt looks forward to further cooperation with Reliance and that the Egyptian Drug Authority is ready to provide all possible technical and procedural support, facilitate partnerships with local counterparts, and facilitate procedures for presence and competitiveness in the Egyptian pharmaceutical market.

He also praised the strength of the Egyptian pharmaceutical market and its regional rise, noting that pharmaceutical market sales reached EGP 307 billion last year, compared to EGP 216 billion in 2023. Furthermore, 3.5 billion packages were traded last year, compared to 3.7 billion packages in 2023. From EIPICO, Dr. Marwan Soliman, General Manager; Dr. Amal Abdel Khaleq, Director of Regulatory Affairs and Pharmacovigilance; Ms. Pranjali Prashant, Vice President of Reliance Life Sciences India; and Mr. Ritesh Kumar, General Manager of the company's India office from the Egyptian Drug Authority, Dr. Asmaa Fouad, Head of the Central Department of Biopharmaceuticals; and Dr. Osama Hatem, Assistant to the President of the Authority for Policy and International Cooperation and Supervisor of the Central Department of Drug Policies and Market Support.

The meeting comes within the framework of the Egyptian Drug Authority's strategy to develop drug policies and strengthen international partnerships, with the goal of improving the quality of healthcare for Egyptian citizens and achieving a balance between the availability of medicines at reasonable prices and ensuring their quality and effectiveness.